共 65 条
Human Amniotic Mesenchymal Stem Cells Inhibit aGVHD by Regulating Balance of Treg and T Effector Cells
被引:11
作者:
Gao, Ya
[1
]
Li, Weiru
[1
]
Bu, Xiaoyin
[1
]
Xu, Ying
[1
]
Cai, Shengchun
[1
]
Zhong, Jinman
[1
]
Du, Meixue
[1
]
Sun, Haitao
[2
]
Huang, Liping
[3
]
He, Yongjian
[4
]
Hu, Xiumei
[4
]
Liu, Qifa
[1
]
Jin, Hua
[1
]
Wang, Qian
[2
,4
]
Ping, Baohong
[5
]
机构:
[1] Southern Med Univ, Nanfang Hosp, Dept Hematol, Guangzhou 510515, Peoples R China
[2] Southern Med Univ, Zhujiang Hosp, Dept Lab Med, Guangzhou 510280, Peoples R China
[3] Southern Med Univ, Nanfang Hosp, Dept Obstet & Gynecol, Guangzhou 510515, Peoples R China
[4] Southern Med Univ, Nanfang Hosp, Dept Lab Med, Guangzhou 510515, Peoples R China
[5] Southern Med Univ, Huiqiao Med Ctr, Nanfang Hosp, Dept Hematol, Guangzhou 510515, Peoples R China
关键词:
acute graft versus host disease;
humanized mouse model;
NPG mice;
amniotic mesenchymal stem cells;
immunomodulatory;
VERSUS-HOST-DISEASE;
STROMAL CELLS;
BONE-MARROW;
IMMUNOMODULATORY PROPERTIES;
MOUSE MODEL;
PROLIFERATION;
TRANSPLANTATION;
PREVENTION;
T(H)17;
GVHD;
D O I:
10.2147/JIR.S323054
中图分类号:
R392 [医学免疫学];
Q939.91 [免疫学];
学科分类号:
100102 ;
摘要:
Background: Acute graft versus host disease (aGVHD) remains a leading cause of transplant-related mortality following allogeneic haematopoietic cell transplantation (allo-HCT). Human amniotic mesenchymal stem cells (hAMSCs) are a novel mesenchymal stem cells (MSCs), which have stronger proliferation and immunomodulatory ability compared with bone marrow mesenchymal stem cells (BM-MSCs). Besides, as the amniotic membrane is often treated as medical waste after delivery, hAMSCs can be obtained conveniently and noninvasively. The aim of this study was to explore the therapeutic efficacy and underlying mechanisms of hAMSCs transplantation for the humanized aGVHD mouse model. Methods: We established a humanized aGVHD mouse model by transplanting human peripheral blood mononuclear cells (PBMCs) into NOD-Prkdc(scid)IL2r gamma(null) (NPG) mice, human amniotic membrane collected from discarded placenta of healthy pregnant women after delivery and hAMSCs were extracted from amniotic membrane and expanded in vitro. Mice were divided into untreated group (Control), aGVHD group (aGVHD), and hAMSCs treatment group (aGVHD+hAMSCs), the hAMSCs labeled with GFP were administered to aGVHD mice to explore the homing ability of hAMSCs. T effector and regulatory T cells (Tregs) levels and cytokines of each group in target organs were detected by flow cytometry and cytometric bead array (CBA), respectively. Results: We successfully established a humanized aGVHD mouse model using NPG mice. The hAMSCs have the ability to inhibit aGVHD in this mouse model through reduced villous blunting and lymphocyte infiltration of the gut while reducing inflammatory edema, tissue destruction and lymphocyte infiltration into the parenchyma of the liver and lung. hAMSCs suppressed CD3+CD4+ T and CD3+CD8+ T cell expression and increased the proportion of Tregs, and besides, hAMSCs can reduce the levels of IL-17A, INF-gamma, and TNF in aGVHD target organs. Conclusion: The NPG murine environment was capable of activating human T cells to produce aGVHD pathology to mimic aGVHD as in humans. The hAMSCs controlled aGVHD by decreasing inflammatory cytokine secretion within target organs by modulating the balance of Tregs and T effector cells in humanized mice.
引用
收藏
页码:3985 / 3999
页数:15
相关论文